Okairos begins Phase I/II trial for first-in-class HCV vaccine
This article was originally published in Scrip
Executive Summary
Clinical-stage biopharmaceutical company Okairos has started the first Phase I/II trial of its potential first-in-class vaccine to prevent hepatitis C virus (HCV) infection, under a collaboration with the US NIH's National Institute of Allergy and Infectious Diseases (NIAID).